Project Grant R03AR084261
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$160K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
New York, NY 10031, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $221,100.00 to the University of Massachusetts Medical School to develop and evaluate in vivo gene editing strategies to repair collagen mutations in mouse models of Osteogenesis Imperfecta (OI). The goal is to use bone-targeting recombinant adeno-associated virus (rAAV) to deliver...
This federal Project Grant award of $483,070 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to investigate the dynamics of bone extracellular matrix (ECM) assembly and resorption. The research aims to determine how osteogenic cellular dynamics, differentiation, and cell fate are integrated with collagen assembly and mineralization, as well as...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $219,605 to fund research on the role of the mechanosensitive ion channel PIEZO1 in the development of post-traumatic osteoarthritis (PTOA). The primary objectives are to: 1) characterize the bi-directional regulation of canonical Wnt/β-catenin signaling and PIEZO1...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $216,850 to the University of California, Los Angeles (UCLA) for a research project titled "Genetic Determinants of Endoplasmic Reticulum Stress in OI and Its Consequences on Cellular Receptors." The research aims to investigate the genotype-dependent accumulation of misfolded type I collagen...
This Project Grant award for $375,100.00, granted by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to identify myeloid progenitors that aid in maintenance of cortical bone with age and characterize cells/molecules that promote coupling within cortical bone. The two-year project, awarded on September 20, 2024 with an ultimate completion date of August 31,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $395,537 to Brigham & Women's Hospital Inc. to develop CRISPR/Cas9-based genome editing strategies to correct pathogenic CLCN7 mutations that cause osteopetrosis, a rare genetic skeletal disorder. The grant funding supports research to optimize editing techniques in hematopoietic...
This $322,408 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support Syracuse University's research on the role of calcium signaling in 3D osteocyte networks and their influence on the bone's mechanoadaptive response. The project aims to define how mechanical stimuli modulate calcium signaling across 3D osteocyte networks, determine...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $147,656 in funding to The Children's Hospital of Philadelphia Research Institute to conduct research on skeletal patterning and growth plate chondrocyte regulation. The research aims to thoroughly define the skeletal phenotypes of mice with inactivated Runx2 and Runx3 genes, identify...
This Project Grant award of $680,325 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research aimed at understanding the critical mechanisms of collagen proteostasis and assessing the therapeutic potential of proteostasis network-targeted interventions for the treatment of collagenopathies. The key products and services to be delivered under this 5-year award...
This federal Project Grant award of $651,662 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify key downstream mediators and potential therapeutic targets regulated by the TGF-β pathway in articular cartilage and osteoarthritis (OA) pathogenesis. The research aims to establish the transcription factor NFIA as a crucial regulator of lipid...